Partner Content Partner Content 5 Key Reasons Why You Should Attend Europe's Leading Ophthal... 5 Key Reasons Why You Should Attend
News Novartis next generation eye drug outperforms Eylea Brolucizumab could offer quarterly dosing schedule.
News Novartis takes aim at Shire and Allergan with dry-eye drug Swiss company takes option on Lubris' ECF843.
News Shire looks to eye drug as sales beat forecasts Company reports better than expected full year figures.
News Novartis to buy ophthalmology firm Encore Vision Swiss pharma buys treatment for common age-related vision problem.
R&D The long-delayed promise of the microbiome, with Sam Possemi... Sam Possemiers, CEO of MRM Health, believes that the microbiome space is finally coming into maturity.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
